Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2020 Filed Apr 23, 2020 21:28 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000124 · wf-form4_158767728408441.xml · derivative · entry 1 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 6 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 5 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 4 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 3 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 2 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:29 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000128 · wf-form4_158767737657631.xml · derivative · entry 1 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 6 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 5 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 4 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 3 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 2 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:27 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000123 · wf-form4_158767726021095.xml · derivative · entry 1 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 169,960 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 12 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,960 Underlying: Class C Ordinary Shares · 169,960 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 169,960 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 11 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 169,960 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 339,754 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 10 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,754 Underlying: Class C Ordinary Shares · 339,754 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 339,754 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 9 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 339,754 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 45,448 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 8 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,448 Underlying: Class C Ordinary Shares · 45,448 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 45,448 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 7 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 45,448 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 90,917 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 6 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,917 Underlying: Class C Ordinary Shares · 90,917 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 90,917 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 5 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 90,917 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights A · Derivative | 170,684 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 4 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,684 Underlying: Class A Ordinary Shares · 170,684 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights A · Derivative | 170,684 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 3 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 170,684 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights A · Derivative | 45,660 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 2 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,660 Underlying: Class A Ordinary Shares · 45,660 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:30 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights A · Derivative | 45,660 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000129 · wf-form4_158767739855768.xml · derivative · entry 1 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 45,660 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights C · Derivative | 65,369 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 12 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,369 Underlying: Class C Ordinary Shares · 65,369 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 65,369 | Not disclosed Strike: $27.34 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 11 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 65,369 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights C · Derivative | 130,674 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 10 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,674 Underlying: Class C Ordinary Shares · 130,674 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 130,674 | Not disclosed Strike: $25.84 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 9 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 130,674 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights C · Derivative | 13,381 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 8 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,381 Underlying: Class C Ordinary Shares · 13,381 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 13,381 | Not disclosed Strike: $29.05 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 7 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 13,381 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights C · Derivative | 26,769 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 6 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,769 Underlying: Class C Ordinary Shares · 26,769 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights C · Derivative | 26,769 | Not disclosed Strike: $27.13 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 5 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 26,769 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights A · Derivative | 65,647 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 4 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,647 Underlying: Class A Ordinary Shares · 65,647 shares Expires 2023-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights A · Derivative | 65,647 | Not disclosed Strike: $27.71 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 3 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 65,647 shares Expires 2020-06-24 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
GrantShare Appreciation Rights A · Derivative | 13,444 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 2 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,444 Underlying: Class A Ordinary Shares · 13,444 shares Expires 2023-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 21:31 UTC |
Salvato AndreaSVP, CHIEF DEVELOPMENT OFFICER
|
Disposition to issuerShare Appreciation Rights A · Derivative | 13,444 | Not disclosed Strike: $29.45 | Not disclosed |
DisclosureSEC source: 0001570585-20-000132 · wf-form4_158767747897706.xml · derivative · entry 1 Salvato Andrea · CIK 0001778743 · SVP, CHIEF DEVELOPMENT OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 13,444 shares Expires 2020-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 6 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 5 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 4 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 3 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 2 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:32 UTC |
SPARKMAN J CDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000133 · wf-form4_158767750516256.xml · derivative · entry 1 SPARKMAN J C · CIK 0001216551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
GrantShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 6 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,614 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 4,614 | Not disclosed Strike: $28.82 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 5 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 4,614 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
GrantShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 4 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,985 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 9,985 | Not disclosed Strike: $26.77 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 3 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 9,985 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
GrantShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 2 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2023-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 17:30 UTC |
RAPLEY DAVID EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,634 | Not disclosed Strike: $29.22 | Not disclosed |
DisclosureSEC source: 0001570585-20-000130 · wf-form4_158767743235834.xml · derivative · entry 1 RAPLEY DAVID E · CIK 0001195192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,634 shares Expires 2020-06-28 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:17 UTC |
BRACKEN CHARLES H REVP & CFO
|
GrantShare Appreciation Rights C · Derivative | 354,766 | $0.00 Strike: $15.12 | $0.00 |
DisclosureSEC source: 0001570585-20-000096 · wf-form4_158594861889669.xml · derivative · entry 10 BRACKEN CHARLES H R · CIK 0001091974 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,766 Underlying: Class C Ordinary Shares · 354,766 shares Expires 2030-04-01 F4 · derivative.exercise_date: The Share Appreciation Rights vest in three equal annual installments commencing on May 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.